Skip to main content
Fig. 2 | Diagnostic Pathology

Fig. 2

From: Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study

Fig. 2

Association between the OS of the lung adenocarcinoma patients in different TNM stages/ treated with different therapeutic modalities, with ERCC1 expression. a Longer OS of the patients with TNM stage I – III/ treated with chemotherapy combined with radiotherapy or surgery, was associated with the low ERCC1 expression compared to the same TNM staged patients and high ERCC1 expression (p = 0.002). b Among the patients in TNM stage IV/treated only with chemotherapy based on platinum, those who had low ERCC1 expression in tumor, had longer OS compared with the same TNM staged patients and high ERCC1 expression (p < 0,001)

Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us